Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trials
作者： Stephen C. Harris , Joel Morganroth , Steven R. Ripa , Michael D. Thorn , Salvatore Colucci
DOI: 10.1080/00325481.2017.1270156
关键词: Anesthesia 、 QT interval 、 Healthy subjects 、 Heart rate 、 Naltrexone 、 Confidence interval 、 Moxifloxacin 、 Placebo 、 Buprenorphine 、 Medicine
摘要: … dose, placebo, or moxifloxacin in the second study. QT intervals were corrected for heart rate … 40, and BTDS 80 on QT intervals was compared with the moxifloxacin-positive control after …
sci-hub.se 参考文章(18)
David P. Kao, Mark C. P. Haigney, Philip S. Mehler, Mori J. Krantz, Arrhythmia associated with buprenorphine and methadone reported to the Food and Drug Administration Addiction. ,vol. 110, pp. 1468- 1475 ,(2015) , 10.1111/ADD.13013
Joseph P Kitzmiller, Christopher J Barnett, Nathan S Steiner, Nicoleta Stoicea, Nawal Kamar, Jasmine A Luzum, Eduard Mikulik, Sergio D Bergese, Buprenorphine: revisiting the efficacy of transdermal delivery system Therapeutic Delivery. ,vol. 6, pp. 419- 422 ,(2015) , 10.4155/TDE.15.3
Mats Karlsson, Anna-Carin Berggren, Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 μg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: A 12-week, randomized, open-label, controlled, parallel-group noninferiority study Clinical Therapeutics. ,vol. 31, pp. 503- 513 ,(2009) , 10.1016/J.CLINTHERA.2009.03.001
Craig J. Landau, William D. Carr, Albert J. Razzetti, Nelson E. Sessler, Catherine Munera, Steven R. Ripa, Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study. Clinical Therapeutics. ,vol. 29, pp. 2179- 2193 ,(2007) , 10.1016/J.CLINTHERA.2007.10.010
Babette Kögel, Thomas Christoph, Wolfgang Straβburger, Elmar Friderichs, Interaction of μ-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice European Journal of Pain. ,vol. 9, pp. 599- 611 ,(2005) , 10.1016/J.EJPAIN.2005.02.002
Robert B. Raffa, Zhe Ding, Examination of the preclinical antinociceptive efficacy of buprenorphine and its designation as full- or partial-agonist Acute Pain. ,vol. 9, pp. 145- 152 ,(2007) , 10.1016/J.ACPAIN.2007.07.002
Borje Darpo, Thierry Nebout, Philip T. Sager, Clinical Evaluation of QT/QTc Prolongation and Proarrhythmic Potential for Nonantiarrhythmic Drugs: The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 Guideline The Journal of Clinical Pharmacology. ,vol. 46, pp. 498- 507 ,(2006) , 10.1177/0091270006286436
Harald Breivik, Tone Marte Ljosaa, Kristian Stengaard-Pedersen, Jan Persson, Hannu Aro, John Villumsen, Dorthe Tvinnemose, A 6-months, randomised, placebo-controlled evaluation of efficacy and tolerability of a low-dose 7-day buprenorphine transdermal patch in osteoarthritis patients naïve to potent opioids Scandinavian Journal of Pain. ,vol. 1, pp. 122- 141 ,(2010) , 10.1016/J.SJPAIN.2010.05.035
Catherine Munera, PhD, Margaret Drehobl, MD, Nelson E. Sessler, PharmD, Craig Landau, MD, A randomized, placebo-controlled, double-blinded, parallel-group, 5-week study of buprenorphine transdermal system in adults with osteoarthritis Journal of opioid management. ,vol. 6, pp. 193- 202 ,(2010) , 10.5055/JOM.2010.0017
Ram P. Kapil, Alessandra Cipriano, Gregory H. Michels, Peter Perrino, Sarah A. O’Keefe, Manjunath S. Shet, Salvatore V. Colucci, Robert J. Noveck, Stephen C. Harris, Effect of Ketoconazole on the Pharmacokinetic Profile of Buprenorphine following Administration of a Once-Weekly Buprenorphine Transdermal System Clinical Drug Investigation. ,vol. 32, pp. 583- 592 ,(2012) , 10.1007/BF03261913